In-line products Our business units In-line Ophthalmics To drive continued growth we focus on commercial excellence across our business units.
Rare In 2014 we achieved strong Diseases results for all our top products.
GI & Internal Neuroscience Medicine Year on year product growth 18% VYVANSE 7% VPRIV 8% at CER 2014 2014 2013 2013 20% LIALDA MEZAVANT 55% FIRAZYR 2014 2014 2013 2013 9% ELAPRASE 11% at CER -2% INTUNIV 2014 2014 2013 2013 1 30% CINRYZE 3% PENTASA 2014 2014 2013 2013 7% REPLAGAL 10% at CER 0% Other products 2014 2014 2013 2013 2% ADDERALL XR 3% at CER 2014 2013 1 On a pro forma basis, 2013 sales recorded by ViroPharma prior to acquisition by Shire.
14 SHIRE PLC ANNUAL REPORT 2014 Strategic Report Governance Financial Statements Other Information Products $million VYVANSE REPLAGAL INTUNIV $1,449m $500m $327m 2013 $1,228m 2013 $468m 2013 $335m ADHD Fabry disease ADHD VYVANSE product sales grew strongly up 18% REPLAGAL sales were up 7% compared to INTUNIV product sales were down 2% in 2014 primarily due to the benefi t of price 2013 up 10% on a CER basis, driven primarily compared to 2013, refl ecting the impact of increases and to a lesser extent higher US by higher unit sales as we continue to see an generic competition from December 2014, prescription demand and growth in ex-US increase in the number of patients on therapy resulting in lower prescription demand, product sales.
This growth was partially with good growth in emerging markets and to a signifi cantly higher sales deductions as a offsetby a lower level of stocking in 2014 lesser extent Europe.
The benefi t of higher unit percentage of product sales and destocking as ascompared to 2013. sales was partially offset by foreign exchange.
compared to a slight level of stocking in 2013.
This was partially offset by price increases taken in 2014.
The impact of generic competition saw INTUNIV market share fall to 2.3% at the end of 2014 from 4.6% at the beginning of the year.
LIALDA MEZAVANT ADDERALL XR PENTASA $634m $383m $290m 2013 $529m 2013 $375m 2013 $281m Ulcerative Colitis ADHD Ulcerative Colitis The 20% growth in product sales for LIALDA ADDERALL XR product sales were up 2% PENTASA product sales were up 3% as the MEZAVANT in 2014 was primarily driven by in2014, as a result of higher prescription benefi t of price increases was partially offset by higher prescription demand up 25% and to demand, partially offset by lower stocking higher sales deductions and a lower prescription alesser extent a price increase taken at the in2014 compared to 2013. demand in 2014 compared to 2013. beginning of 2014.
The growth was partially offset by a lower level of stocking and higher sales deductions as a percentage of sales in 2014 as compared to 2013.
ELAPRASE VPRIV $593m $367m 2013 $546m 2013 $343m Hunter syndrome Gaucher disease ELAPRASE sales growth was up 9% up 11% VPRIV sales were up 7% up 8% on a CER on a CER basis, driven by continued growth basis, driven by a strong performance in the inthe number of treated patients, especially EUand US as we continue to add nave inemerging markets.
Sales growth was also patientsand gain patients switching from other negatively impacted by foreign exchange.
Sales growth was also negatively impacted by foreign exchange.
CINRYZE FIRAZYR $503m $364m 2013 n a 2013 $235m For the prophylactic treatment of Hereditary For the treatment of acute HAE attacks Angioedema FIRAZYR sales growth was up 55% compared Shire acquired CINRYZE through its acquisition to 2013, driven by a higher number patients on of ViroPharma on January 24, 2014.
CINRYZE therapy and the effect of a price increase in the sales were $503 million in 2014, growing 30% US market.
1 on a pro-forma basis on 2013 primarily driven by more patients on therapy and to a lesser extent the impact of a price increase in the US, and an increase in channel inventory.
1 2013 recorded by ViroPharma, prior to the acquisition of ViroPharma by Shire.
